Campbell & CO Investment Adviser LLC Acquires New Shares in Colfax Co. (NYSE:CFX)


Share on StockTwits

Campbell & CO Investment Adviser LLC acquired a new stake in Colfax Co. (NYSE:CFX) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 12,644 shares of the industrial products company’s stock, valued at approximately $484,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in CFX. Psagot Investment House Ltd. acquired a new position in Colfax in the third quarter valued at approximately $42,000. Private Capital Group LLC acquired a new position in Colfax during the fourth quarter worth $42,000. US Bancorp DE lifted its stake in Colfax by 214.2% during the fourth quarter. US Bancorp DE now owns 2,429 shares of the industrial products company’s stock worth $93,000 after purchasing an additional 1,656 shares in the last quarter. ProShare Advisors LLC acquired a new position in Colfax during the third quarter worth $224,000. Finally, RPG Investment Advisory LLC acquired a new position in Colfax during the fourth quarter worth $250,000. Hedge funds and other institutional investors own 99.56% of the company’s stock.

NYSE CFX opened at $44.91 on Tuesday. Colfax Co. has a 1 year low of $12.23 and a 1 year high of $45.46. The company has a market capitalization of $5.32 billion, a PE ratio of -898.20, a P/E/G ratio of 2.61 and a beta of 2.15. The company has a fifty day moving average of $39.74 and a two-hundred day moving average of $35.27. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.64 and a quick ratio of 0.96.

Colfax (NYSE:CFX) last announced its earnings results on Wednesday, February 17th. The industrial products company reported $0.51 earnings per share for the quarter, topping the consensus estimate of $0.50 by $0.01. Colfax had a negative net margin of 0.24% and a positive return on equity of 6.04%. On average, research analysts expect that Colfax Co. will post 1.38 earnings per share for the current year.

A number of research analysts have commented on the company. JPMorgan Chase & Co. restated a “buy” rating and set a $52.00 price target on shares of Colfax in a research note on Tuesday, November 24th. UBS Group raised Colfax from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $36.00 to $40.00 in a research report on Monday, November 9th. Citigroup upped their price objective on Colfax from $35.00 to $41.00 in a research report on Monday. Morgan Stanley upped their price objective on Colfax from $30.00 to $39.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 15th. Finally, KeyCorp upped their price objective on Colfax from $36.00 to $44.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 18th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and nine have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $36.90.

In related news, CFO Christopher M. Hix sold 4,483 shares of the firm’s stock in a transaction dated Monday, December 14th. The shares were sold at an average price of $37.41, for a total value of $167,709.03. Following the completion of the sale, the chief financial officer now owns 59,449 shares in the company, valued at $2,223,987.09. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Shyam Kambeyanda sold 2,357 shares of the firm’s stock in a transaction dated Monday, December 14th. The shares were sold at an average price of $37.41, for a total transaction of $88,175.37. Following the completion of the sale, the executive vice president now owns 54,855 shares of the company’s stock, valued at approximately $2,052,125.55. The disclosure for this sale can be found here. Insiders have sold 28,879 shares of company stock valued at $1,096,011 in the last quarter. Insiders own 12.00% of the company’s stock.

About Colfax

Colfax Corporation operates as a diversified technology company worldwide. The company operates through two segments, Medical Technology and Fabrication Technology. The Medical Technology segment offers orthopedic solutions, including orthopedic devices and braces, reconstructive and surgical implants, footwear, bone growth stimulators, and software and services spanning the full continuum of patient care, as well as injury prevention, rehabilitation, pain management, and physical therapy under the Aircast, Chattanooga, CMF, Compex, DonJoy, ProCare, DJO Surgical, Dr.

See Also: Return on Investment (ROI) Defined, Explained

Want to see what other hedge funds are holding CFX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colfax Co. (NYSE:CFX).

Institutional Ownership by Quarter for Colfax (NYSE:CFX)

Receive News & Ratings for Colfax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colfax and related companies with MarketBeat.com's FREE daily email newsletter.